A Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IDX184 After Oral Administration in Healthy Subjects

Trial Profile

A Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IDX184 After Oral Administration in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs IDX 184 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 04 May 2009 Results presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009).
    • 26 Apr 2009 Results presented at EASL 2009.
    • 10 Dec 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top